Tavin EM is taken in combination with other antiretroviral medications to treat adults infected with HIV-1. Tavin EM combines two anti-HIV medications, tenofovir disoproxil fumarate and emtricitabine, in a single pill; however, Tavin EM still must be taken with at least one other anti-HIV drug to halt the progression of HIV to AIDS.
One pill should be orally administered with or without food once a day, every day at the same time. Due to the risk of kidney problems associated with Tavin EM, patients with lowered renal functions, defined as having a creatinine clearance of 30 to 49 ml/min, may take one pill every 48 hours. Patients who have a creatinine clearance of less than 30 ml/min should avoid taking Tavin EM.
Patients who are hypersensitive to either of Tavin EM's core ingredients, emtricitabine or tenofovir disoproxil fumarate, should avoid Tavin EM.
The most widely reported adverse of effects of Tavin EM are:
Less common adverse effects that have been reported are:
Patients taking Tavin EM have reported other adverse effects in smaller quantities. Inform your doctor if you feel any changes in your health after starting Tavin EM.
Patients taking Tavin EM for the first time may experience symptoms of immune reconstitution syndrome during the first few weeks of treatment. Due to Tavin EM's potential toxicity, everyone taking Tavin EM should have their renal functions regularly monitored. Patients' blood should also be monitored at regular intervals to make sure the HIV viral load remains under control. More research needs to be done to establish the safety of Tavin EM in patients who have underlying liver disorders. Sudden discontinuation of Tavin EM has been linked to hepatitis flare ups in individuals infected with hepatitis B. Long term use of anti-HIV drugs has been known to cause changes in patients' physical appearance including redistribution of body fat and weakened bone structure. Talk to your doctor if you start to notice any physical changes after starting Tavin EM.
Taking Tavin EM with acyclovir, valacyclovir, valganciclovir, ganciclovir or cidofovir may increase the patient's risk of renal problems. Administering Tavin EM with didanosine can worsen the adverse effects of didanosine. Taking Tavin EM with atazanavir and lopinavir/ritonavir may exacerbate the adverse effects of Tavin EM. Patients taking Tavin EM should not take atazanavir without ritonavir.
No risks to the fetus have been observed in laboratory test with pregnant animals being administered Tavin EM, but no research has yet been done on pregnant humans. Mothers with HIV should not breastfeed because of the potential risk of HIV transmission to the infant.
When taken in high doses, Tavin EM is potentially toxic. Seek out medical attention as soon as possible if you take more than prescribed. A hemodialysis or haemodialysis may be necessary to rid the body of the excess drug.